IDP Pharma utilizes its proprietary INTRAMETICS™ platform to develop direct inhibitors targeting intrinsically disordered proteins (IDPs), which are critical drivers of various cancers, including multiple myeloma and glioblastoma. The company aims to create effective therapies that activate the degradation of these proteins, addressing the unmet medical needs in treating complex diseases.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Intrinsically disordered proteins (IDPs) are key drivers in many cancers, including multiple myeloma and glioblastoma, but have historically been difficult to target with traditional drug discovery methods. Current approaches often involve targeting upstream or downstream pathways, which can be less effective due to multiple and redundant mechanisms.
Solution
IDP Pharma utilizes its INTRAMETICS™ platform to develop direct inhibitors of intrinsically disordered proteins (IDPs). The INTRAMETICS™ platform facilitates the design of molecules that directly engage and activate the degradation of IDPs through the cell's intrinsic machinery. This protein-centric approach counters all deregulation mechanisms of IDPs, including epigenetic, genetic, transcriptional, translational, and post-translational modifications. The company's next-generation peptidomimetics offer advantages in size, specificity, plasticity, and stability, enabling the development of breakthrough treatments for cancers and other incurable diseases. IDP-121, a direct cMyc protein inhibitor and degrader, is currently in Phase 1/2 clinical trials for MYC-driven hematological cancers.
Target Audience
The primary target audience includes patients with cancers driven by intrinsically disordered proteins, as well as clinicians and researchers focused on developing novel cancer therapies.
Features
- INTRAMETICS™ platform for designing drugs that directly target and degrade IDPs
- Next-generation peptidomimetics with enhanced size, specificity, plasticity, and stability
- Protein-centric approach that counters all deregulation mechanisms of IDPs
- IDP-121, a direct cMyc protein inhibitor and degrader in Phase 1/2 clinical trials
- Focus on developing treatments for cancers driven by IDPs, such as multiple myeloma and glioblastoma